Incidence of FGFR2 Amplification and FGFR2 Fusion in Patients with Metastatic Cancer Using Clinical Sequencing

Figure 2

Clinicopathological landscape of patients with different cancer types exhibiting FGFR2 amplification. (a) Venn diagram showing the percentage distribution of tumor types with FGFR2 amplification (21 cases): GC (85.7%), sarcoma (9.5%), and CRC (4.8%). (b) FGFR2 copy number. (c) Analysis of the correlation between PD-L1 level and FGFR2 copy number. (d) Patient profiles, including the distribution of FGFR2 copy number of all patients, tumor type and FGFR2 amplification level (top), age and sex (middle), and MSI, TMB, and PD-L1 status (bottom). MSI: microsatellite instability; PD-L1: programmed cell death-ligand 1; TMB: tumor mutational burden.

(a)

(b)

(c)

(d)